Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan

Glioblastoma multiforme (GBM) carries a dismal prognosis despite the current standard of multimodality treatments. Recent studies showed promising results to a regimen consisting of a VEGF inhibitor, (bevacizumab) and a topoisomerase I inhibitor (irinotecan) [BI] in recurrent GBM. However, those pat...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Almubarak, Mohammed, Newton, Michael, Altaha, Ramin
Format: Artigo
Langue:Inglês
Publié: Hindawi Publishing Corporation 2008
Sujets:
Case Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2648641/
https://ncbi.nlm.nih.gov/pubmed/19259336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2008/942618
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires